Europe Fill Finish Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecules, Large Molecules), By Product Type (Sterile, Non-sterile), By End-use, By Region, And Segment Forecasts 2023 - 2030

Report Overview

The Europe fill finish pharmaceutical contract manufacturing market size was valued at USD 2.2 billion in 2022 and is expected to expand at a lucrative compound annual growth rate (CAGR) of 6.1% over the forecast period. Several factors have contributed to the expansion of the fill-finish pharmaceutical contract manufacturing market in Europe. The rising frequency of chronic disease and the aging population’s increased demand for pharmaceutical products as well as the rising trend to outsource pharmaceutical manufacturing to Contract Manufacturing Organizations (CMOs), are some of the key factors driving the market. Additionally, the regulatory environment in Europe is favorable for contract manufacturing, which is also contributing to the growth of the market. Furthermore, advancements in technology and the increasing use of contract manufacturing by pharmaceutical companies are expected to drive market growth.

The fill-finish pharmaceutical contract manufacturing market in Europe involves the production of sterile injectable drugs, including vaccines, biologics, and other pharmaceuticals. The market is also driven by factors such as the increasing demand for sterile injectable drugs and the growing focus on cost containment and efficiency by pharmaceutical companies. Adding to it, there is a growing trend towards the use of contract manufacturing by small and mid-sized pharmaceutical companies, as well as by virtual biotech companies are also the prime factor to boost the overall market in Europe.

The COVID-19 pandemic has had a significant impact on the pharmaceutical industry, including the fill-finish contract manufacturing market in Europe. One of the major impacts of the pandemic on the fill-finish contract manufacturing market in Europe has been an increased demand for COVID-19 vaccines and therapies. This has put pressure on manufacturers to increase production and scale up their operations to meet the demand. Many CMOs have been working around the clock to meet this demand, and some have even expanded their production facilities to increase capacity. Another impact of the pandemic has been increased scrutiny of pharmaceutical manufacturing processes, as regulators seek to ensure that products are being produced safely and effectively. This has led to changes in regulatory requirements and increased oversight of manufacturing facilities, which has added to the complexity and cost of fill-finish operations. Overall, the COVID-19 pandemic has had a significant impact on the fill-finish contract manufacturing market in Europe.

Molecule type Insights

The small molecule segment dominated the market with a revenue share of over 61.9% in 2022. Small molecules are widely used in the treatment of various diseases, including cancer, cardiovascular diseases, and infectious diseases, which is driving the demand for small molecule-based pharmaceutical products. Additionally, the cost-effectiveness of small molecule-based drugs compared to biologics and biosimilars is also contributing to the growth of small molecules in the market. Moreover, the small molecule fill-finish pharmaceutical contract manufacturing market has become increasingly competitive due to the entry of several new players in recent years. Companies are expanding their capabilities and investing in advanced technologies to improve their production efficiency, increase yield, and reduce costs. As a result, small-molecule drugs are expected to continue to dominate the fill-finish pharmaceutical contract manufacturing market in the coming years.

On the other hand, the large molecule is anticipated to witness lucrative growth over the forecast period with a CAGR of 7.1%. Biologics are large, complex molecules that are often made from living cells and are used to treat a variety of illnesses, including cancer, autoimmune conditions, and genetic problems. The market for large-molecule fill-finish contract manufacturing is expanding owing to the rising demand for large-molecule pharmaceuticals and the complexity of their manufacturing process.

Product Type Insights

Sterile accounted for the largest revenue share of 52.2% in 2022 as well as it is anticipated to witness lucrative growth over the forecast period with a CAGR of 7.5%. The rise of the sterile product category is being driven by the rising demand for biologics and biosimilars, as these goods need to be manufactured using sterile techniques in order to be safe and effective. Second, as sterile products are employed in the treatment of numerous ailments, the increased prevalence of chronic diseases in Europe is further fueling demand for these segments. Additionally, the favorable regulatory environment in Europe for contract manufacturing is contributing to the growth of the sterile product type, as manufacturers are required to adhere to strict quality standards to obtain regulatory approval.

Moreover, the COVID-19 pandemic has further increased demand for sterile injectables as vaccines and treatments need to be produced & filled in sterile environments. A notable example of this growth is the recent acquisition of Bristol-Myers Squibb’s biologics fill-finish and oral solid dose facility in Anagni, Italy, by Catalent.

End-use insights

The biopharmaceuticals segment dominated the market and accounted for the largest revenue share of 54.7% in 2022. The increasing demand for biologics and biosimilars is driving the growth of the biopharmaceutical end-use segment. Biopharmaceuticals are widely used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, which is driving the demand for biopharmaceutical products. Due to the market for biologics and biosimilars experiencing rapid expansion, biopharmaceutical companies are the main consumers of fill-finish contract manufacturing services. It is difficult for companies to produce biologics in-house since they are complex compounds that call for specific production techniques and tools. To concentrate on their core strengths, biopharmaceutical companies are increasingly outsourcing their fill-finish processes to CMOs.

On the other hand, the pharmaceutical companies segment is anticipated to witness lucrative growth over the forecast period with a CAGR of 7.5%. Pharmaceutical companies are increasingly outsourcing fill-finish operations their fill-finish operations to Contract Manufacturing Organizations (CMOs) to focus on their core competencies, such as R&D. Moreover, with the increasing complexity of biologics and personalized medicines, several pharmaceutical companies lack the necessary expertise and equipment to handle fill-finish operations in-house. Outsourcing to CMOs enables them to access specialized expertise and state-of-the-art facilities, resulting in improved efficiency and reduced costs.

Regional Insights

Germany dominated Europe’s fill-finish pharmaceutical contract manufacturing market with a revenue share of over 22.7% in 2022, as well as expected to register the fastest rate with a CAGR of 6.5% over the forecast period.  The fill-finish pharmaceutical contract manufacturing scenario in Germany is a robust and highly regulated industry. This contract manufacturing is typically performed by specialized companies that have the necessary expertise, equipment, and facilities to handle a wide range of pharmaceutical products. These companies are subject to strict regulations from the German regulatory agency-the Federal Institute for Drugs and Medical Devices (BfArM)-and must adhere to the GMP guidelines. In addition, Germany's central location in Europe and well-developed transportation infrastructure make it an ideal location for pharmaceutical companies looking to distribute their products throughout Europe.

Key Companies & Market Share Insights

The market is highly competitive, and market players are undertaking numerous strategic initiatives, such as acquisitions, collaborations, and partnerships, to gain a greater market share. For instance, in 2022, Gerresheimer AG and Stevanato Group announced their collaboration for the creation of an advanced fully prepared vial device for the pharmaceutical industry, with the aim of helping clients improve fill-finish process accuracy, speed, & quality standards in the pharmaceutical and medical devices markets. Some prominent players in Europe fill finish pharmaceutical contract manufacturing market include:

• Thermo Fisher Scientific, Inc.

• Sartorius AG

• Boehringer Ingelheim

• Catalent, Inc.

• Societal CDMO (Recro Pharma, Inc)

• Baxter BioPharma Solutions

• Eurofins Scientific

• Symbiosis Pharmaceutical Service

• MabPlex International Co. Ltd.

• Recipharm AB

• Fresenius Kabi Contract Manufacturing

• Lonza

Europe Fill Finish Pharmaceutical Contract Manufacturing Market Report Scope

Europe Fill Finish Pharmaceutical Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented Europe fill finish pharmaceutical contract manufacturing market report based on molecule type, product type, end-use, and region:

• Molecule Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Small Molecule

  • Large Molecule

• Product Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Sterile

    • Prefilled Syringes

    • Vials

    • Cartridges

    • Others

  • Non- sterile

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Biopharmaceutical Companies

  • Pharmaceutical Companies

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • Europe

    • U.K.

    • Germany

    • Italy

    • France

    • Spain

    • Denmark

    • Sweden

    • Norway

    • Switzerland

    • Belgium

    • Rest of Europe